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1. Introduction
Neuroblastoma is a neural crest-derived embryonal malignancy of the postganglionic
sympathetic division of the peripheral autonomic nervous system. It is the most frequent extra
cranial solid malignancy of childhood and the most common cancer in children less than one
year of age. It accounts for 7% of childhood cancers and 15% of all childhood cancer deaths. It
most commonly occurs sporadically but familial cases can also occur with one subdivision
attributable to germline mutation of the PHOX2B gene and another due to germline ALK gene
mutations [1,2,3,4]. Recurring chromosomal aberrations are detected in this disease and three
major genomic subdivisions represent greater than 80% of cases; i.e. hyperdiploid neuroblas‐
toma; near diplod neuroblastoma that has 17q gain and 11q deletions; and MYCN amplified
neuroblastoma with 17q gain and 1p deletion [5,6,7,8]. A whole-genome analysis and assess‐
ment of structural defects in 87 primary neuroblastomas found few recurrent amino-acid
changing mutations, with ALK mutations in 6%, but identified local shredding of chromo‐
somes (chromothripsis) in 18% of high stage neuroblastomas. High stage tumours that did not
have amplifications of MYCN had recurrent structural alterations in genes involved in cone
stabilisation and neuritogenesis [9]. Indeed in this study tumours with a genomic signature
involving defective genes responsible for neuritogenesis or growth cone guidance were mostly
aggressive high-stage tumours.
Activating mutations of the anaplastic lymphoma kinase (ALK) genes and amplification of the
MYCN oncogene can occur in neuroblastoma. The ALK gene resides on chromosome 2p23
centromeric to the MYCN locus on chromosome 2q24. Approximately 2-3% of cases of
neuroblastomas have amplification of ALK and these occur almost invariably concomitant
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with amplification of MYCN [10]. However, amplification of the ALK gene without concom‐
itant MYCN gene amplification can occur, for example a particularly informative case of a
neuroblastoma with a high level amplicon involving and solely limited to the ALK gene was
described by French investigators in 2008 in one of the landmark papers that established the
importance of ALK in neuroblastoma [11]. Activating ALK mutations are found in 80% of
familial cases and 6-11% of sporadic cases. It is considered that once the expression of wild
type ALK exceeds a certain threshold it can have oncogenic activity[10]. Twenty percent of all
cases of neuroblastomas have amplification of MYCN which is associated with a worse
prognosis and can be used to stratify treatment. This chapter appraises the current knowledge
and potential therapeutic implications arising from ALK and MYCN abnormalities in neuro‐
blastoma. In a concluding reflection the chromosomal proximity and interaction of these genes
as well as the potential for therapeutic advancement in neuroblastoma is discussed.
2. The anaplastic lymphoma kinase gene in neuroblastoma
2.1. The ALK gene
The anaplastic lymphoma kinase gene is a 200kDa member of the insulin receptor super family.
It is an orphan tyrosine kinase receptor and has homology with the MET oncogene and the
neurotrophin receptor. It is normally expressed by the developing nervous system and at a
much lower level in the nervous system of adults [12]. In mouse embryo studies Alk transcripts
were detected in the central nervous system (CNS) and peripheral nervous system. E15
embryos had expression in the Gasserian ganglion of the trigeminal nerve (cell bodies of V1,
V2 and sensory component V3) as well as the superior cervical ganglion, posterior root ganglia
of the spinal cord and the myenteric plexus of the enteric nervous system. In the 1 week old
mouse Alk transcripts are clustered in particular neuronal regions in the CNS such as the
mesencephalon, thalamic nuclei which act as relay stations for nerve impulses and olfactory
bulb, mitral cells and tufted cells that receive primary afferents from olfactory epithelial
neurones. Relatively high levels of Alk transcripts were present in the superior colliculus,
which is the centre of visual sensation and the red nucleus, a crucial part of the rubrospinal
tract which regulates the contraction of flexor muscles [13]. Lower levels were detected in the
hypothalamus, inferior colliculus, subiculum, cerebral cortex and cerebellum (Purkinje’s cells
and Golgi cells). Interestingly one patient in a phase 1 study of an ALK inhibitor in children
with relapsed/refractory ALK-driven tumors (57 evaluated for toxicity) developed grade 3
dizziness [14]. It remains speculative as to whether it is possible to attribute it to cerebellar Alk
expression based on the finding of low level Alk expression in the murine cerebellum.
The anaplastic lymphoma kinase gene has a restricted pattern of expression in adults in that
it is expressed in testis, small intestine and brain but is not expressed in normal lymphoid
tissue. It has been shown to be important in the pathogenesis of ALK positive anaplastic large
cell lymphoma, inflammatory myofibroblastic tumours and adenocarcinoma of the lung
(NSCLC) [15]. Its importance in cancer was first described in 1994 in anaplastic large cell
lymphoma where a translocation (2; 5) (p23; q35) fuses NPM a non-ribosomal nucleolar
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phosphoprotein with ALK in 50-75% of cases [16]. The most frequent abnormality involving
ALK in non-small cell lung cancer is an inversion of a segment of chromosome 2 creating a
chimeric fusion gene involving ALK and the Echinoderm microtubule-associated protein;
ALK-EML4 [17]. In inflammatory myofibroblastic tumours, tropomyosin TMP3 or TMP4
create fusion oncoproteins with ALK. Clonal rearrangements at chromosome 2p23 occur in
50% of these tumours [18]. More recently ALK protein expression has been seen in rhabdo‐
myosarcomas with 81% of cases of the alveolar subtype having strong cytoplasmic staining
for ALK compared to 31% of cases of the embryonal subtype. These subtypes have gene copy
number gain of 88% and 52% respectively. In the embyonal subgroup ALK aberrations were
associated with disease progression and outcome [19].
The ALK receptor is a dependence receptor and in the absence of ligand enhances apoptosis
by autologous cleavage by caspase [12]. Therefore ALK belongs to the subcategory of onco‐
genes in which inappropriate expression in a cellular context or in the absence of ligand can
induce apoptosis. This is considered to be a mechanism to abrogate frequent tumour formation
if oncogenes become deregulated. Myc is also considered to be an established comparator gene
in this respect. Additionally in the visual system of Drosophila ALK in the presence of a ligand
appears essential for axonal guidance. It is known that perturbations of the visual system, in
particular in the first 5 years of life can cause amblyopia [20, 21]. Also, in an expanded cohort
study of 82 adults with ALK positive NSCLC treated with crizotinib, mild visual disturbances
were reported by 41% of patients. These were most frequently described as trails of light
following moving objects particularly seen with changes in ambient lighting usually improv‐
ing with duration of time receiving treatment [22]. It may be the case that the aforementioned
finding of Alk transcripts in the superior colliculus of the 1 week old mouse is relevant as the
superior colliculus is important for saccadic and smooth pursuit eye movements. Though not
described to date in patients with neuroblastoma treated with ALK inhibitors, given the age
demographics of patients with neuroblastoma it is the author’s contention that clinicians
conducting ongoing trials need to be cognisant of the theoretical potential to damage the
developing neuroanatomical visual system with resulting amblyopa. The visual system
includes the optic nerves, optic chiasma and optic tracts; the lateral geniculate body a swelling
beneath the posterior projection of the pulvinar of the thalamus and the geniculoclcarine tract
which originates within the lateral geniculate body and terminates at the calcarine sulcus of
the medial surface of the cerebral hemisphere. Evaluation of the regional ALK status of this
system is a subject for further research.
2.2. ALK in neuroblastoma
Neuroblastoma is considered to be a malignancy derived from the embryonic neural crest.
Evidence of neuroblastoma being derived from neural crest progenitor cells are (i) neuroblas‐
toma primary sites are anatomically consistent with arising from the sympatho-adrenergic
lineage of neural crest differentiation (ii) The gene expression patterns of neuroblastomas and
neural crest progenitor cells are similar [23] (iii) In situ neuroblastomas occur in the adrenal
glands of 1/200 newborns with most spontaneously regressing later in life and there is a
histological similarity to residual nests of sympathogonia [24].
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A small proportion of cases of neuroblastoma display autosomal dominant Mendelian
inheritance patterns and a familial history of neuroblastoma is elicited in 1-2% of cases [25, 26,
27]. There is a standardized incidence ratio of 9.7 for disease occurrence in siblings of index
cases [28]. Previously it had been recognized that neuroblastoma can arise in the context of
concurrent neurocristopathies related to abnormal development of neural-crest derived
tissues such as concomitant Hirschsprung’s disease or central congenital hypoventilation
syndrome. Nonsense and missense mutations of the homeobox gene PHOX2B were shown to
predispose to this abnormality of the sympathoadrenal lineage [4, 29, 30].
In October 2008 four articles were published in the journal Nature that established the impor‐
tance of aberrations in ALK as a feature of some neuroblastomas [11,31,32,33]. Mossé and
colleagues of Children’s Hospital Philadelphia found that ALK is a major neuroblastoma
predisposition gene with germline ALK mutations accounting for most cases of familial
neuroblastoma [31]. Using a whole-genome scan of neuroblastoma pedigrees (8 unrelated
families) a significant linkage signal at 2p23-24 was identified. Re-sequencing 194 high risk
neuroblastomas found somatically acquired ALK mutations in 12.4% of cases. Most mutations
mapped to the kinase domain of ALK and caused constitutive phosphorylation. Cell line
studies also showed that knockdown of ALK mRNA caused growth inhibition suggesting that
therapeutics targeting ALK may have clinical efficacy in neuroblastoma.
In another study lead by investigators at Dana Farber Cancer Institute, Boston mutations of
ALK were found in 8% of primary neuroblastomas [32]. A genome wide study of primary
neuroblastomas identified amplification of the ALK gene. Analysis of 94 tumours with
amplification of MYCN found 14 (15%) with concomitant ALK amplification. This was not
identified in 51 tumors without MYCN amplification. DNA resequencing of the ALK open
reading frame identified in primary neuroblastomas found 5 non-synonymous sequence
variations in the ALK tyrosine kinase domain in 7 of 93 samples (8%). The most frequent
mutation which was in 4.3% (4) of the 93 cases was a cytosine to adenine alteration in exon 23
causing a phenylalanine to leucine substitution in codon 1174 (F1174L). This mutation was
also found in 3 different neuroblastoma cell lines. Three of the mutations were somatic and 2
were germline. Interestingly 4 of the 5 identified mutations involved residues which corre‐
spond to those that are affected by activating EGFR gene mutation. The ALK 1174 residue
correlated with V769 in EGFR and ERBB2 [34]. A F1245C ALK mutation correlated with the
L833V mutation in EGFR, which is a gefitinib resistant mutation in NSCLC. The R1275Q
mutation is positioned adjacent to the homologous position of L858R in EGFR, the most
common mutation of EGFR in NSCLC [35, 36]. ALK cDNA encoding either the F1174L or the
R1275Q variants transformed interleukin-3 dependent murine hematopoietic Ba/F3 cell lines
to cytokine independent cell growth. Furthermore these autonomously growing cells were
sensitive to the ALK inhibitor TAE684. Additionally 2 human neuroblastoma cell lines were
sensitive to TAE684. It has been observed by Mossé and colleagues that there are disorder
involving oncogenes such as RET in medullary thyroid cancer arising in the context of multiple
endocrine neoplasia type 2 and MET in papillary carcinoma of the kidney that are analogous
to the sequential ‘two hit model’ of Knudson. Knudsons’ was first used to describe retinoblas‐
toma arising from aberrations of a tumor suppressor gene. In the oncogene ‘two hit’ model the
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second hit is a somatically acquired duplicate of the mutant allele or mutant gene amplification
[37]. In neuroblastoma oncogenic activation of ALK can occur by mutation of the tyrosine
kinase domain and for example with respect to a ‘second hit’ in the Dana Farber led study,
ALK gene amplification was found in 15% of 94 tumours with MYCN amplification.
French investigators assessed ALK copy number variation by comparative genomic hybridi‐
zation in 592 cases of neuroblastomas [11]. Within this group 26 cases (4.4%) had in excess of
a twofold copy number increase of ALK and a further 135 cases (22.8%) had lower level gains.
The level of expression of ALK is strongly correlated with copy number [38]. Within the
genomic analysis a subcategory without MYCN amplification was assessed using 100K single
nucleotide polymorphism arrays. A notable case within this cohort was an instance of
neuroblastoma with a high level amplicon involving and solely limited to the ALK gene. Also
a series of 28 cell lines and 115 tumor samples found 16 ALK mutations grouped into 2 main
hotspots. The F1174L mutation was seen in one primary tumor but was more frequent in cell
lines suggesting that this particular mutation confers an in vitro growth advantage. Cell lines
are usually over-represented by metastatic tumors with a greater propagating potential and
this finding may be vicarious evidence of the F1174L mutation being correlated with a poorer
clinical outcome. Finally a Japanese study identified 8 novel missense mutations in the ALK
gene in 13 out of 215 cases of neuroblastoma (6.1%) and 8 of 33 (33%) neuroblastoma cell lines.
The mutated kinases could transform NIH3T3 fibroblasts and form tumors in nude mice [33].
These four studies were a landmark advance in the field, however later a European group of
international collaborators performed a meta-analysis of 709 neuroblastomas (254 new cases
and 455 previously published) to comprehensively described the correlation of ALK mutation
type and frequency with clinical and genomic factors. They also assessed the prognostic
significance of ALK copy number and expression [39]. Mutations in ALK were detected in
6.9% of cases with a mutation frequency of ALK of 5.7% in favorable (International neuro‐
blastoma Staging System INSS 1, 2 and 4s) cases and 7.5% in unfavorable tumors (INSS 2 and
4). There was no statistical difference with respect to mutation frequency between the favorable
and unfavorable groups (P=0.087). Mutation hot spots R1275Q (49%) and F1174L (34.7%) were
observed within the mutated cases. However the F1174L mutations occurred in a greater
proportion of the MYCN amplified cases (P=0.0001) and the concurrence of a F1174L mutation
in a MYCN amplified neuroblastoma was found to confer an especially poor prognosis. It was
described that there was a skewed ALK mutation spectrum within the MYCN amplified cohort
with over-representation of the F1174L mutation. F1174 mutated ALK was present in 1.3% of
single copy MYCN tumors compared with 6.1% of MYCN amplified tumors. To consider it
another way, within the 17 cases of F1174 ALK mutated neuroblastoma 58.8% had amplifica‐
tion of MYCN compared to a rate of 21.6% in cases of neuroblastoma with wild type ALK.
There also was no difference in the frequency for MYCN amplification between the R1275Q
cases and wild type ALK. The skewed distribution of F1174L mutations being overrepresented
in MYCN amplified cases of neuroblastoma was also confirm in 27 neuroblastoma cell lines
most of which were MYCN amplified. Five had the F1174L mutation with only one case of
R1275Q mutant neuroblastoma found. F1174 mutated neuroblastoma compared to the R1275Q
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mutant variant had a greater transforming ability with a higher amount of auto phosphory‐
lation. Gain in Chr. 2p that included ALK (91.8%) also was correlated with poor survival.
2.3. Possible new treatments for neuroblastoma that target ALK
Crizotinib is an orally bio-available small molecule that inhibits the tyrosine kinase activity of
ALK and c-Met which is approved by the U.S. Food and Drug administration for the treatment
of cases of NSCLC that have rearrangements of the ALK gene. Crizotinib competes with
adenosine triphosphate to bind to the ALK tyrosine kinase. The two most common ALK
mutations in neuroblastoma are F1174L and R1275Q and both mutations promote autophos‐
phorylation of the ALK tyrosine kinase region. F1174 mutated ALK in particular is a more
lethal variant. Using neuroblastoma cell lines and xenograft models it has been shown that
different ALK mutations can affect both kinase activity and inhibitor sensitivity [40]. Both
F1174L and R1275Q ALK mutations cause amino acid substitutions in the intracellular tyrosine
kinase domain of the ALK receptor and constitutively activate the ALK tyrosine kinase
domain. Neuroblastoma cell lines and xenograft mouse models that expressed R1275Q-ALK
are sensitive to crizotinib. By comparison F1174L mutated ALK cell lines were relatively
resistant to crizotinib. The Km, ATP for F1174L of ~0.127Mm was approximately 2.3 times lower
than the Km, ATP of 0.326 for the R1275Q mutant ALK variant. The F1174L mutation combines
the characteristics of an activating gene mutation and a resistance mutation, increasing kcat and
maintaining a wild type like Km, ATP. The derived overall inference of these findings is that
comparative crizotinib resistance of the F1174L mutant ALK is due to greater ATP binding
affinity and it is hoped that the resistance may be overcome by increasing the doses of crizotinib
or using ALK inhibitors with increased affinity to the ALK tyrosine kinase domain.
The U.S. National Cancer Institute is sponsoring a phase I/II study of crizotinib in children
with relapsed or refractory solid tumors and anaplastic large cell lymphoma. The phase I study
was presented at the American Society of Clinical Oncology Annual Meeting in Chicago, June
2012 (Protocol IDs: COG-ADVL0912, ADVL0912, NCT00939770) by Yael Mossé; abstract 9500
[14]. The study enrolled 70 patients with confirmed ALK fusion proteins, mutations or
amplification with 57 fully evaluable for toxicity. This was a heterogeneous study population
with respect to cancer type and included other cancers in addition to neuroblastoma. Six
different dose levels of crizotinib were evaluated using the rolling-six design and dosing was
bid on 28 day cycles without interruption. The recommended phase II dose that emerged was
280mg/m2/dose. Seven of eight (88%) of patients with anaplastic large cell lymphoma had a
complete response (2 differing dose levels). 27 patients in the trial had neuroblastomas. Within
the cohort of neuroblastoma cases with a known ALK mutation (n=8), one patient had a
complete response and 2 had stable disease. Of the 19 patients with neuroblastoma and an
unknown ALK status, 1 had a complete response and 6 had prolonged stable disease.
With respect to toxicity there were two grade 5 cases of haemorrhage within the central nervous
system in patients with neuroblastoma and the protocol was updated to exclude patients with
a previous history of central nervous system involvement. Other toxicities observed within
the study and not necessarily within the neuroblastoma subgroup were grade 4 transaminitis
(n=1), grade 4 neutropenia (n=1) and grade 3 dizziness (n=1). A discussant at the meeting
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Thomas Gross of The Ohio State University Nationwide Children’s Hospital referenced some
Crizotinib toxicities observed in adults with NSCLC including gastrointestinal complaints,
transient vision disorders, self-limited lower testosterone levels and rare renal cysts. He felt
that these toxicities necessitated further investigation in the paediatric population. Regarding
efficacy he noted that there can be variability in oncogenic partners with ALK within chimeric
fusion genes in differing disease types that may partly account for the rates of complete
responses seen in different malignancies. He also observed that some responses were seen in
ALK negative cases in the phase 1 trial. Phase II data on the efficacy and toxicity of Crizotinib
in neurblastoma will be required.
3. The MYCN gene in neuroblastoma
3.1. The MYCN family
MYC is a pleotropic evolutionary conserved family of basic helix-loop-helix leucine zipper
transcription factors, comprising c-Myc, L-Myc and N-Myc [41, 42]. These transcription factors
regulate the expression of ~15% of all genes [43, 44]. MYC proteins have numerous roles in
malignancy with roles of special importance in neuroblastoma being that of driving cellular
proliferation and angiogenesis while concurrently inhibiting apoptosis and maintaining the
neoplastic ‘stem cell’ compartment. MYCN is amplified in ~20% of cases of neuroblastoma and
amplification of MYCN is independently correlated with a higher disease stage and a poor
clinical outcome. It is amplified in 40% of cases with a high risk phenotype. It has been
contended that targeting Myc is a therapeutically attractive strategy to treat cancer but
difficulties persist. These include (i) Myc exerts effects by protein-protein and protein-DNA
interactions. Small molecule inhibitors have not usually been effective in this context. (ii) Most
Myc aberrations in malignancies are not due to intrinsic abnormalities of Myc but rather due
to ‘upstream’ aberrant oncogenic signals causing it’s induction (iii) Myc is required for stem
cell compartment maintenance and proliferation in normal tissues with a theoretical concern
of serious bystander tissue toxicities [45] (iv) Analysis of the role of c-Myc and N-Myc in cancer
is difficult to assess in tissues as embryonic lethality is conferred by germline deletion of these
genes. Much of the data on the consequences of inhibiting Myc is derived from conditional
knockouts of the c-Myc gene using Cre mediated recombination which can be very variable
and unpredictable in the extent of c-myc deletion in the cells targeted (iv) Conditional knockout
models are irreversible and therefore not good representative models of transient inhibition
of Myc conferred by inhibitor medications.
One particularly important experimental example of Myc inhibition was in an adenocarcinoma
of lung murine model [45]. Omomyc is a competitive inhibitor of Myc-dependent gene
transcription by preventing the binding of Myc to its consensus E-box CACGTG DNA elements
thereby preventing Myc binding to its obligate dimerization partner Max. This prevents the
transactivation of its target genes. Omomyc may also augment Myc-dependent trans repres‐
sion [46, 47]. The LSL-KrasG12D murine model of NSCLC has irreversible activation of oncogenic
KRasG12D driven by the kras promoter when it inhales adenovirus expressing Cre recombinase.
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This causes multifocal lung tumours to occur within 18 weeks. Shut down of Myc transacti‐
vation using transgenic Omomyc expression caused profound tumour reduction within 3 days
and mice become overtly tumour free after 28 days [45]. Reassuringly murine tissue integrity
was maintained with no major unexpected toxicities emerging. Considering neuroblastoma,
treatments directed at MYCN are particularly appealing as genetic mouse models with MYCN
targeted to neural crest tissue develop tumours which are similar to neuroblastomas [48].
3.2. MYCN in neuroblastoma
Double minutes and homogeneously staining regions are the cytogenetic hallmarks of
genomic amplification in malignancies. Neuroblastoma karyotyes frequently have these
cytogenetic markers and MYCN amplifications are often found [49]. Tumours that have an
aggressive phenotype frequently have amplification of the MYCN oncogene and amplification
of MYCN is correlated with the extent of disease at diagnosis [50]. Correlative International
Neuroblastoma Staging System (INSS) stage at diagnosis and the respective frequency of
MYCN amplification described by data from the Children’s Oncology Group Statistical Office
are; Stage 1, 3%; Stage 2a/2b, 4%; Stage 3, 25%; Stage 4, 32% and Stage 4s, 8% ( Wendy, London;
John, Maris, Principles and Practice of Paediatric Oncology, page 890). Amplification of MYCN
is normally detected by interphase FISH with a usual increase in copy number of 50 to 400
copies in neuroblastomas and a cut off of 4 times the normal copy number being the definition
of MYCN amplification by many pathologists. Other genes can be co-amplified with MYCN
[51, 52]. Also comparative genomic hybridisation of tumours arising in a transgenic mouse
model that overexpresses MYCN in neuroectodermal cells, found losses and gains of at least
seven chromosomal regions. These were syntenic with comparable abnormalities detected in
human neuroblastomas [52].
NVP-BEZ235 a dual inhibitor of the phosphatidylinositol 3-kinase (PI3K)/mammalian target
of rapamycin (mTOR) pathway decreases levels of MYCN protein and suppresses tumour
proliferation and angiogenesis in neuroblastomas [53]. This partly arises because MYCN in
tumour cells contributes to paracrine signalling between tumour cells and endothelial cells. It
has previously been shown that blocking PI3K/mTOR causes destabilisation of MYCN protein
with reduced VEGF secretion and inhibition of progression of neuroblastomas in murine
models [54]. A study published in Science Translational Medicine in 2012 by Chanthery and
colleagues provided new information as to the separate ‘intrinsic’ and ‘paracrine’ including
‘anti-angiogenic’ mediated anti-tumour effects of inhibiting PI3K/mTOR signalling in neuro‐
blastomas using NVP-BEZ235. Improved survival was seen in two mouse models, the first a
xenograft tumour derived from a patient (MYCN-amplified human orthoptic xenograft) and
the second a MYCN dependent transgenic model (transgenic for TH-MYCN; that recapitulates
a MYCN amplified tumour arising in an autochthonous site) in which MYCN causes sponta‐
neous tumour formation in mice. In both models there were reductions in tumour growth
without tumour regression. This was attributed to a reduction in proliferation of neuroblasts
and decreased tumour vascular density. PI3K inhibition caused de-repression of GSK3β with
consequential Thr58 phosphorylation and destabilisation of MYCN with a remarkable
reduction in MYCN levels in tumours treated with NVP-BEZ235.
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To establish tumour cell autonomous effects of NVP-BEZ235 on MYCN degradation, HUWE1
knockdown tumour cells (deficient in PI3K/mTOR-mediated MYCN proteolysis; a Thr58
mutant MYCN) were used to establish orthoptic xenograft models. It was demonstrated that
HUWE1 were resistant to the anti-angiogenic effects of NVP-BEZ235 showing that MYCN was
a critical target in vivo and part of the anti-angiogenic effect is a consequence of the transcrip‐
tion regulatory function of MYCN. It is possible that NVP-BEZ235 may emerge as a new
therapeutic choice for the treatment of neuroblastoma.
4. ALK and MYCN
4.1. ALK and MYC co-operating neighbours
ALK and MYCN are the only established oncogenes in neuroblastoma [55, 56]. ALK mutations
occur at an equal frequency in both low and high risk neuroblastomas and within all genomic
subtypes which is suggestive that mutations within the ALK gene are not the only molecular
aberrations that drives oncogenesis in this disease [57]. ALKF1174L mutated neuroblastomas
are more common within the high risk neublastoma category [10]. In neuroblastoma cell line
studies overexpression of wild type or mutated ALK stimulates the transcription of MYCN
and the concurrent expression of MYCN and activated ALK increases the in vitro transfor‐
mation of NIH3T3 cells [58].
A series of experiments on pathogenic cooperation between ALK and MYCN were conducted
using a transgenic zebrafish model of neuroblastoma in which MYCN induced tumour arose
from a subpopulation of neuroblasts which migrate to the interrenal gland, the zebrafish
equivalent of the adrenal medulla (50% of neuroblastomas in humans arise in the adrenal
medulla) [59]. Sympathoadrenal precursors in the interrenal gland co-express the cholami‐
nergic enzymes tyrosine hydroxylase and dopamine-β-hydroxylase as well as neuronal
specific Hu proteins. In this model the dopamine-β-hydroxylase promoter was used to drive
EGFR-MYCN expression. Using this experimental model it was found that 17.3% of MYCN
induced zebrafish develop neuroblastomas. Transgenic zebrafish that expressed wild type
ALK or that expressed F1174L mutant ALK did not develop neuroblastomas. Activated ALK
accelerate the onset of neuroblastoma and increased the penetrance of MYCN-induced
neuroblastoma with a 3 fold increase for fish co-expressing both MYCN and ALK F1174L
compared to wild type or F1174L mutant ALK fish. The mechanism as to how neuroblastomas
arise within the zebrafish model was also investigated. MYCN overexpressing transgenic fish
has an increased number of Hu+ neuroblasts that fail to differentiate resulting in increased cell
number with reduced numbers of chromaffin cells compared to controls at 3-5 weeks post
fertilization (wpf). An apoptotic response significantly reduced the number of these Hu+ cells
at the 5-7 wpf interval. In the presence of a cooperating activated ALK there is continuous
accumulation of Hu+ neuroblasts with failure of differentiation but there is decreased apop‐
tosis of high penetrance and transformed neuroblastoma. Overall it has been inferred that ALK
mutant F1174L attenuates the sequential apoptotic response in MYCN transformed Hu+
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neuroblasts constituting the ‘second’ hit when considering it as an oncogenic equivalent of the
Knudson ‘two hit’ model.
Another study found that ALK regulates the initiation of MYCN transcription in neuroblas‐
toma [58]. ALK (including wild type ALK and mutated variants) stimulated the transcription
of MYCN mRNA by affecting the MYCN promoter in neuronal and neuroblastoma cell lines.
Similarly the transcription of MYCN can be abrogated by using ALK inhibitors such as
crizotinib or NVP-TAE684. A series of experiments found that ALKF1174L or ALKR1275Q mediated
a marked transformation of NIH3T3 cells but MYCN alone or wild type ALK failed to initiate
cellular transformation. Co-transfection of ALK1174L concurrent with MYCN caused a 3 fold
increase in transformation compared to activated ALKF1174L alone. Results consistent with this
finding were seen when ALKR1275Q was expressed with MYCN. It was consistently noted that
ALKF1175L has a greater transforming potential than ALKR1275Q 60. Overall it appears that ALK
drives the initiation of MYCN transcription. Concomitant expression of a constitutively active
mutant ALK variant causes increased transformation and MYCN protein levels compared with
expression of ALKF1174L, ALKR1275Q or MYCN alone. Trials of ALK inhibitors alone in neuro‐
blastoma may not succeed as dysregulation of MYC is the main ‘oncogenic driver’ in the
disease and initiation of MYCN transcription can occur by ways other than by the mutation
or amplification of ALK.
5. Recent therapeutic advances in neuroblastoma and the promise of
targeted therapies changing the treatment paradigm
The treatment of neuroblastoma varies according to risk group stratification and prognosis.
Therefore prognosis needs to be considered first prior to contextualizing recent therapeutic
advances.
5.1. Prognosis
Phenotypic and prognostic variation occurs in neuroblastoma as some clinical phenotypes
spontaneously regress while other patients have rapidly progressive high risk disease in which
despite intensive myeloablative chemotherapy relapses are common and almost invariably
fatal [61,62]. Neuroblastoma prognosis can be subdivided into low risk, intermediate risk, high
risk, and stage 4S disease [63]. The U.S. National Cancer Institute also has listed different
subdivisions of neuroblastoma. Firstly neuroblastomas can be subdivided into three biologi‐
cally discrete types of tumor. These categories can be used to sub-stratify patient prognosis
but do not have treatment implications [64,65].
Type 1: Hyperdiploid, expression of TrkA neurotropin receptor. Tends to spontaneously
regress.
Type 2: Expression of TrkB neurotropin receptor and its ligand. Additional copy of chromo‐
some 17q, loss of heterozygosity 14q or 11q. Genome unstable.
Type 3: Gain chromosome 17q, loss of chromosome 1p, MYCN amplification.
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There also is a risk assignment system in North America that has been used clinically by the
Children’s Oncology Group in studies such as COG-9641 and COG-A3961 [66, 67]. It has
categories of low, intermediate and high-risk based on INSS stage, age, and tumor biology.
Tumor biology characteristics considered are International Neuroblastoma Pathologic
Classification (INPC), MYCN status and tumor DNA index. The INPC system involves the
evaluation of pre-treatment tissue for the amount of stromal development, the mitosis-
karyorrhexis index and the degree of neuroblastic maturation [68,69,70,71]. Stage 4S disease
though included in these studiers is a particular case.
5.1.1. Treatment advances in high risk neuroblastoma in the ‘ ALK Era’
In 2009 long term outcomes of 379 patients with high risk neuroblastoma (CCG-3891) all of
whom received the same induction treatment (5 cycles’ cisplatin, doxorubicin, etoposide and
cyclophosphamide plus surgery and received radiotherapy for residual local and metastatic
disease) was reported [72]. Subsequent to induction patients were randomly assigned to
consolidation with myeloablative chemotherapy, total body irradiation, and autologous
purged bone marrow transplantation versus 3 cycles of intensive chemotherapy (cisplatin,
etoposide, doxorubicin and ifosfamide). Of the participants that completed consolidation
without disease progression, they were randomly assigned to no further therapy or 6 cycles
of 13-cis retinoic acid (160mg/m2/d in 2 divided doses for 14 days every 28 days). Myeloablative
therapy and autologous hematopoietic rescue had a significantly better 5 year event free (~30%
versus ~19%) and overall survival compared with non-myeloablative chemotherapy. 13 cis-
retinoic acid after consolidation independently lead to significantly improved overall survival.
5 year overall survival from time of second random assignment for patients who underwent
both sequential randomisations is documented in table 1.
Treatment randomly assigned to 5-year overall survival
ABMT / 13-cis retinoic acid 59%+/-8%
ABMY / no 13-cis retinoic acid 41%+/-7%
Continuing chemotherapy / 13-cis retinoic acid 38%+/-7%
Chemotherapy / no 13-cis retinoic acid 36%+/-7%
Table 1. please add caption
In 2010 a new treatment advance was reported in high risk neuroblastoma involving ch14.18
a chimeric human-murine anti-GD2 monoclonal antibody that targets GD2 a disialoganglio‐
side tumour associated antigen [73]. Patients that had a response to induction therapy and
stem-cell transplantation were treated with immunotherapy (six cycles of isotretinoin and five
concomitant cycles of ch14.18 in combination with alternating GM-CSF and interleukin-2). This
regimen was found to be better than standard treatment ( six cycles of isotretinoin) with a 2
year event free survival rate of 66% compared to 46% respectively, P=0.02.
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High risk disease has a generic treatment paradigm of intensive chemotherapy to induce
remission followed by surgery, radiotherapy and myeloablative chemotherapy. A presenta‐
tion at the 2011 ASCO Annual meeting changed the treatment standard for high risk disease.
The HR-NLB1 trial was a comparator trial between two high dose myeloablative chemother‐
apeutic regimens in high risk neuroblastoma. 563 children with stage IV disease (high risk
distant  metastatic  disease or  local  disease;  median age 3 years)  received busulphan and
myelphalan  (281  patients)  or  a  3  drug  chemotherapeutic  combination  of  carboplatin,
etoposide and melphalan (CEM; 282 patients). The 3 year event free survival was 49% versus
33% respectively. The 3 year overall survival was 60% versus 48% again favouring busul‐
phan-melphalan over  CEM. Busulphan-melphalan also  had a  lower  rate  of  relapse  47%
versus 60% [74].
5.1.2. Intermediate risk neuroblastoma advances in the ‘ALK Era’
A phase 3 non randomized trial of newly diagnosed intermediate risk neuroblastoma without
MYCN amplification was performed on 479 patients (323 patients had favourable biology
tumours; 141 patients had tumours with unfavourable biology) [75]. Patients with favourable
histopathology and hyperdiploidly received 4 cycles of chemotherapy (carboplatin, etoposide,
cyclophosphamide and doxorubicin, administered at 3-week intervals) and patients with
unfavourable features or an incomplete response received 8 cycles. The 3 year overall survival
rate was ~ 96% with an overall survival rate of 98% for patients with favourable biology tumour
and 93% for patients with unfavourable biology neuroblastomas. Using this biologic based
risk assignment high rates of survival were preserved in intermediate risk disease with
reduced doses and duration of chemotherapy compared to historic controls (e.g. Children’s
Oncology Group trial CCG-3881; overall survival INSS stage 4s, 92%; stage 4, 93%; stage 3,
100%)[76,77,78]. Recent years have seen advancements in high risk neuroblastoma involving
myleoablative conditioning regimens, 13-cis retinoic acid and immunotherapeutic. However
in intermediate risk disease the evolution of treatment involves preservation of treatment
efficacy using a biologically defined stratification approach with a reduction in the patient
exposure to chemotherapy.
5.1.3. What of ALK and MYC and targeted treatments?
MYC gene transcription can be diminished by targeting BET bromodomainds using small
molecular inhibitors of the BET family of chromatin adaptors [79]. Inhibition of BET bromo‐
domain-promoter interactions with reduced MYC mRNA transcription and translation of
MYC protein caused G1 cycle arrest with apoptosis in a diverse number of lymphoma and
leukaemia cells. There was dysregulation of the MYC transcriptome including reactivation of
the tumour suppressor p21. Treating xenograft models of Burkitt’s lymphoma or acute
myeloid leukaemia with a BET inhibitor demonstrated significant anti-tumour activity.
Activation of the c-MYC gene is the sine qua non of Burkitt’s lymphoma with the c-MYC locus
at Chr. 8q24 involved in t (8;14)(q24;q32) epidemic Burkitt’s lymphoma and other abnormali‐
ties involving the MYC gene in sporadic cases including a different t(8;14) translocation and
point mutation of exon 2 of c-MYC. In neuroblastoma cell lines with MYCN amplification high
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dose transient treatment with (+)-JQ1 (a small molecule enantiomer BET bromodomaine
inhibitor) caused transcriptional repression of MYCN.
Zhu and colleagues in the zebrafish model of neuroblastoma show that ALK F1174L attenu‐
ates MYCN induced apoptosis [59]. Given the previous experience with targeted therapeutics
in other disease types and the emergence of drug resistance it has been contended that respons‐
es to crizotinib are unlikely to be durable [57]. As ALK and MYCN have collaborative roles with
MYCN being the primary oncogenic driver it may be the case that some of the initial optimism
pertaining to Crizotinib in neuroblastoma may not be fulfilled and that dual targeting of ALK
and MYCN once technically feasible may revolutionise the outcome for many patients with
neuroblastoma. In a fascinating caveat it is notable that in MYCN single-copy cases of neuroblas‐
toma, increased MYCN mRNA and protein levels are paradoxically associated with a more
favourable clinical  phenotype.  Gene expression profiling of  251 primary neuroblastomas
identified a core set of MYCN/c-MYC target genes with a successive gradual increase in that
target gene signature in localized non-amplified cases to stage 4s-non amplified followed by
stage 4-non-amplified and finally MYCN amplified cases. High expression of the MYCN/c-
MYC gene signature identified patients with poor overall survival independent of some of the
usual clinico-pathologic variables such as age at diagnosis (> or equal 1.5 years; stage 4 versus
stages 1,2,3, and 4s and amplified MYCN) [80]. It is apparent that MYCN’s role in the quite
heterogenous disease neuroblastoma is complex and the development of targeted therapeu‐
tics in neuroblastoma needs to appreciate these complexities. Of course treatments that target
MYCN remain therapeutic lacunae to be filled. A final ancillary comment on ALK and MYC.
German investigators have designed and performed experiments using JoMa1 which is a
multipotent neural crest progenitor cell line that is kept in an undifferentiated but viable state
by a tamoxifen activated c-Myc transgene (c-MycER T) [81]. Expression of ALKF1174L in primary
neuroblastomas caused in vitro growth of these cells independent of c-MycERT activity and the
in vivo growth of neuroblastoma like tumours. Tumorigenicity was further enhanced by serial
transplantation and remained susceptible to NBT-272 a MYC inhibitor. Therefore it appears that
targeting ALK alone may result in regression of neuroblastoma with the potential to further
augment tumour regression by inhibition of MYC. Maybe new hope for children with neuroblas‐
toma does not fully rely on neighbourly gene relations!
6. Conclusion
The improvement in outcome in neuroblastoma treatment in recent decades is a tremendous
success however outcomes for high risk disease have changed little. The importance of the
ALK gene in this disease and an established ALK inhibitor already being used in other types
of cancer offers new hope for improving outcomes. Therapeutic targeting of Myc is a long
aspired for hope in the wider field of oncology which may be realised. Chromosomal proximity
of genes such as topoisomerase II and Her-2 in breast cancer has been a topical subject but
aside from the concept of co-amplification of genes as in the breast cancer ‘topo II-Her2’
paradigm ALK and Myc interact in many nuanced and therapeutically exploitable ways with
the prospect of many advances still to come.
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